Search

Your search keyword '"Yasuda, Nobuyuki"' showing total 70 results
Start Over Author "Yasuda, Nobuyuki"
70 results on '"Yasuda, Nobuyuki"'

53. Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes

Author

Hiyoshi, Hironobu, primary, Yanagimachi, Mamoru, additional, Ito, Masashi, additional, Yasuda, Nobuyuki, additional, Okada, Toshimi, additional, Ikuta, Hironori, additional, Shinmyo, Daisuke, additional, Tanaka, Keigo, additional, Kurusu, Nobuyuki, additional, Yoshida, Ichiro, additional, Abe, Shinya, additional, Saeki, Takao, additional, and Tanaka, Hiroshi, additional

Published
2003
Full Text
View/download PDF

55. 2-Alkynyl-8-aryladenines possessing an amide moiety: their synthesis and structure–activity relationships of effects on hepatic glucose production induced via agonism of the A2B adenosine receptor

Author

Harada, Hitoshi, primary, Asano, Osamu, additional, Kawata, Tsutomu, additional, Inoue, Takashi, additional, Horizoe, Tatsuo, additional, Yasuda, Nobuyuki, additional, Nagata, Kaya, additional, Murakami, Manabu, additional, Nagaoka, Junsaku, additional, and Kobayashi, Seiichi, additional

Published
2001
Full Text
View/download PDF

57. 2-Alkynyl-8-aryl-9-methyladenines as Novel Adenosine Receptor Antagonists: Their Synthesis and Structure−Activity Relationships toward Hepatic Glucose Production Induced via Agonism of the A2BReceptor

Author

Harada, Hitoshi, primary, Asano, Osamu, additional, Hoshino, Yorihisa, additional, Yoshikawa, Seiji, additional, Matsukura, Masayuki, additional, Kabasawa, Yasuhiro, additional, Niijima, Jun, additional, Kotake, Yoshihiko, additional, Watanabe, Nobuhisa, additional, Kawata, Tsutomu, additional, Inoue, Takashi, additional, Horizoe, Tatsuo, additional, Yasuda, Nobuyuki, additional, Minami, Hiroe, additional, Nagata, Kaya, additional, Murakami, Manabu, additional, Nagaoka, Junsaku, additional, Kobayashi, Seiichi, additional, Tanaka, Isao, additional, and Abe, Shinya, additional

Published
2000
Full Text
View/download PDF

63. Effects of the Combination of a Dipeptidyl Peptidase IV Inhibitor and an Insulin Secretagogue on Glucose and Insulin Levels in Mice and Rats.

Author

Yamazaki, Kazuto, Yasuda, Nobuyuki, Inoue, Takashi, Yamamoto, Eiichi, Sugaya, Yukiko, Nagakura, Tadashi, Shinoda, Masanobu, Clark, Richard, Saeki, Takao, and Tanaka, Isao

Abstract

Several combination therapies have been tried for treating of type 2 diabetes to control more effectively fasting hyperglycemia and postprandial hyperglycemia. In this study, we have examined the effects of combining a novel, selective, and competitive dipeptidyl peptidase IV (DPP-IV) inhibitor, 3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate (E3024), with a representative of one of two types of insulin secretagogues, i.e., either glybenclamide (a sulfonylurea) or nateglinide (a rapid-onset/short-duration insulin secretagogue), on glucose and insulin levels in an oral glucose tolerance test (OGTT) using mice fed a high-fat diet. In addition, we have investigated the effects of these combinations on blood glucose levels in fasting rats. Two-way analysis of variance showed that the combination of E3024 and glybenclamide improved glucose tolerance additively and also caused a synergistic increase in insulin levels in the OGTT in mice fed a high-fat diet. In a similar way, the combination of E3024 and nateglinide ameliorated glucose tolerance additively and raised insulin levels additively. In fasting rats, coadministration of E3024 with glybenclamide or nateglinide treatment did not affect the glucose-lowering effects of the insulin secretagogues. Therefore, a DPP-IV inhibitor in combination with glybenclamide or nateglinide may be a promising option for the treatment of type 2 diabetes, and particularly, for controlling postprandial hyperglycemia in the clinic.

Published
2007
Full Text
View/download PDF

65. Protective Effect of MEG, AET, Serotonin and Phenylephrine Against Bone Marrow Injury Following Whole-body Irradiation of Mice

Author

ナカツカ, ハルオ, オチ, ヒロノブ, フジムラ, テツオ, カガワ, ケイジ, ヤマシタ, アキラ, ヤスダ, ノブユキ, Nakatsuka, Haruo, Ochi, Hironobu, Fujimura, Tetsuo, Kagawa, Keiji, Yamashita, Akira, Yasuda, Nobuyuki, 中塚, 春夫, 越智, 宏暢, 藤村, 哲夫, 香川, 圭爾, 山下, 彰, 安田, 晋之, ナカツカ, ハルオ, オチ, ヒロノブ, フジムラ, テツオ, カガワ, ケイジ, ヤマシタ, アキラ, ヤスダ, ノブユキ, Nakatsuka, Haruo, Ochi, Hironobu, Fujimura, Tetsuo, Kagawa, Keiji, Yamashita, Akira, Yasuda, Nobuyuki, 中塚, 春夫, 越智, 宏暢, 藤村, 哲夫, 香川, 圭爾, 山下, 彰, and 安田, 晋之

Published
1966

67. Staurosporine stimulates insulin gene expression via CRE dependent manner

Author

Shinozuka, Yoriko, Okada, Masayuki, Yasuda, Nobuyuki, and Yokoyama, Kazunari K.

Abstract

We examined various compounds to stimulate the transcription of promoter-reporter construct in pancreatic HIT-T15 cells, that had been stably transfected with the rat insulin I promoter-PLAP reporter gene, and found staurosporine at dose of nano mole enhanced insulin promoter activity significantly. Northern blotting analysis and ELISA (enzyme linked immunosorbent assay) showed that the promoter activity of insulin gene was well correlated with the endogenous level of insulin mRNA and protein in HIT-T15, indicating that staurosporine stimulated the biosynthesis of insulin at levels of transcription and translation. The deletion and point mutation of cAMP response element (CRE) in the promoter region of insulin gene lost the promoter activity of reporter gene induced by staurosporine. These results suggested that insulin promoter activity stimulated by staurosporine is CRE-dependent.

Published
2003
Full Text
View/download PDF

68. Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.

Author

Tanaka Y, Takeuchi T, Umehara H, Nanki T, Yasuda N, Tago F, Kawakubo M, Kitahara Y, Hojo S, Kawano T, and Imai T

Subjects
Adult, Antibodies, Monoclonal immunology, Antibodies, Monoclonal pharmacokinetics, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized immunology, Antibodies, Monoclonal, Humanized pharmacokinetics, Antibodies, Monoclonal, Humanized therapeutic use, Antirheumatic Agents immunology, Antirheumatic Agents pharmacokinetics, Antirheumatic Agents therapeutic use, Female, Humans, Male, Middle Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Humanized adverse effects, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Chemokine CX3CL1 immunology
Abstract

Objective: Fractalkine (CX3CL1/FKN) is a chemokine that regulates chemotaxis and adhesion of CX3C chemokine receptor 1 (CX3CR1)-expressing inflammatory cells. We conducted the first phase 1/2, open-label, multiple ascending dose study of E6011, a humanized anti-FKN monoclonal antibody, in Japanese rheumatoid arthritis (RA) patients (clinicaltrial.gov identifier: NCT02196558)., Methods: Active RA patients with an inadequate response or intolerance to methotrexate or tumor necrosis factor (TNF) inhibitor received E6011 at week 0, 1, 2, and thereafter every 2 weeks for 12 weeks., Results: Twelve, 15, and 10 subjects were enrolled in the 100, 200, and 400 mg cohorts, respectively. No severe adverse events (AEs) or deaths occurred, and no major differences were observed in the incidence or severity of AEs across the cohorts. Serum E6011 concentrations increased dose dependently. American College of Rheumatology (ACR) 20, 50, and 70 responses at week 12 were 75.0%, 33.3%, and 8.3% in the 100 mg cohort; 66.7%, 20.0%, and 13.3% in the 200 mg cohort; and 60.0%, 30.0%, and 20.0% in the 400 mg cohort, respectively., Conclusions: E6011 appeared to be safe and well tolerated in RA patients during this 12-week treatment period, suggesting that E6011 has an effective clinical response in active RA patients.

Published
2018
Full Text
View/download PDF

70. Staurosporine stimulates insulin gene expression via CRE dependent manner.

Author

Shinozuka Y, Okada M, Yasuda N, and Yokoyama KK

Subjects
Genes, Reporter, Insulin metabolism, Promoter Regions, Genetic, RNA, Messenger genetics, Transcription, Genetic drug effects, Gene Expression Regulation drug effects, Insulin genetics, Staurosporine pharmacology
Abstract

We examined various compounds to stimulate the transcription of promoter-reporter construct in pancreatic HIT-T15 cells, that had been stably transfected with the rat insulin I promoter-PLAP reporter gene, and found staurosporine at dose of nanomole enhanced insulin promoter activity significantly. Northern blotting analysis and ELISA (enzyme linked immunosorbent assay) showed that the promoter activity of insulin gene was well correlated with the endogenous level of insulin mRNA and protein in HIT-T15, indicating that staurosporine stimulated the biosynthesis of insulin at levels of transcription and translation. The deletion and point mutation of cAMP response element (CRE) in the promoter region of insulin gene lost the promoter activity of reporter gene induced by staurosporine. These results suggested that insulin promoter activity stimulated by staurosporine is CRE-dependent.

Published
2003
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results